FIELD: medicine.
SUBSTANCE: invention presents a glypican-3 antibody, an anticancer composition, an anticancer drug containing the glypican-3 antibody. There are disclosed a nucleic antibody, a host cell and a method for producing the glypican-3 antibody.
EFFECT: antibody provides improved plasma half-life.
11 cl, 15 dwg, 1 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
| NR10 ANTIBODY AND USING IT | 2008 |
|
RU2531521C2 |
| ANTIBODY AGAINST NR10 AND ITS APPLICATION | 2009 |
|
RU2487136C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| NOVEL ANTI-HUMAN Igβ ANTIBODY | 2015 |
|
RU2710532C2 |
| GLYPICAN-3 ANTIBODY | 2005 |
|
RU2427588C2 |
| HUMANIZED ANTI-EPIREGULIN-ANTIBODY AND ANTI-TUMOUR THERAPEUTIC AGENT CONTAINING THIS ANTIBODY AS ACTIVE INGREDIENT | 2012 |
|
RU2634383C2 |
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
| MODIFIED CONSTANT REGION OF ANTIBODY | 2008 |
|
RU2526512C2 |
